The University of Chicago Header Logo

Connection

Geoffrey Greene to Estrogen Receptor alpha

This is a "connection" page, showing publications Geoffrey Greene has written about Estrogen Receptor alpha.
Connection Strength

5.315
  1. Next-Generation ERa Inhibitors for Endocrine-Resistant ER+ Breast Cancer. Endocrinology. 2019 04 01; 160(4):759-769.
    View in: PubMed
    Score: 0.546
  2. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016 Feb 02; 5.
    View in: PubMed
    Score: 0.439
  3. Estrogen-dependent and -independent estrogen receptor-alpha signaling separately regulate male fertility. Endocrinology. 2009 Jun; 150(6):2898-905.
    View in: PubMed
    Score: 0.272
  4. Modulation of alphaCaMKII signaling by rapid ERalpha action. Brain Res. 2008 Jul 30; 1222:1-17.
    View in: PubMed
    Score: 0.257
  5. An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology. 2008 Jun; 149(6):2970-9.
    View in: PubMed
    Score: 0.254
  6. Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep. 2007 Jun; 8(6):563-8.
    View in: PubMed
    Score: 0.239
  7. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem. 2006 Jun 30; 281(26):17909-19.
    View in: PubMed
    Score: 0.223
  8. Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol Endocrinol. 2005 Dec; 19(12):2930-42.
    View in: PubMed
    Score: 0.212
  9. PARP-1 as a novel target in endocrine-resistant breast cancer. J Exp Clin Cancer Res. 2025 Jun 16; 44(1):175.
    View in: PubMed
    Score: 0.210
  10. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell. 2005 May 13; 18(4):413-24.
    View in: PubMed
    Score: 0.209
  11. Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 06 07; 26(1):95.
    View in: PubMed
    Score: 0.196
  12. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 05 16; 11.
    View in: PubMed
    Score: 0.170
  13. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
    View in: PubMed
    Score: 0.147
  14. The NF-?B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res. 2020 07; 18(7):1018-1027.
    View in: PubMed
    Score: 0.146
  15. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
    View in: PubMed
    Score: 0.133
  16. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chem Biol. 2018 12 21; 13(12):3374-3384.
    View in: PubMed
    Score: 0.133
  17. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018 06; 18(6):377-388.
    View in: PubMed
    Score: 0.129
  18. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017 03; 7(3):277-287.
    View in: PubMed
    Score: 0.117
  19. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor a modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014 Oct; 6(10):1328-46.
    View in: PubMed
    Score: 0.100
  20. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec; 45(12):1439-45.
    View in: PubMed
    Score: 0.094
  21. Prolactin activates ERa in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology. 2013 Dec; 154(12):4483-92.
    View in: PubMed
    Score: 0.093
  22. Cross-talk between the ligand- and DNA-binding domains of estrogen receptor. Proteins. 2013 Nov; 81(11):1900-9.
    View in: PubMed
    Score: 0.093
  23. Mapping ERß genomic binding sites reveals unique genomic features and identifies EBF1 as an ERß interactor. PLoS One. 2013; 8(8):e71355.
    View in: PubMed
    Score: 0.092
  24. RAC3 is a pro-migratory co-activator of ERa. Oncogene. 2011 Apr 28; 30(17):1984-94.
    View in: PubMed
    Score: 0.077
  25. Characterization of the ovarian and reproductive abnormalities in prepubertal and adult estrogen non-responsive estrogen receptor alpha knock-in (ENERKI) mice. Steroids. 2009 Nov; 74(12):913-9.
    View in: PubMed
    Score: 0.070
  26. CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol. 2008 Feb; 22(2):263-72.
    View in: PubMed
    Score: 0.062
  27. Molecular characterization of a B-ring unsaturated estrogen: implications for conjugated equine estrogen components of premarin. Steroids. 2008 Jan; 73(1):59-68.
    View in: PubMed
    Score: 0.061
  28. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem. 2007 Jan 25; 50(2):399-403.
    View in: PubMed
    Score: 0.059
  29. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol. 2004 Dec; 18(12):2854-65.
    View in: PubMed
    Score: 0.049
  30. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol Cell. 2004 Feb 13; 13(3):317-27.
    View in: PubMed
    Score: 0.048
  31. A structural explanation for ERalpha/ERbeta SERM discrimination. Ernst Schering Res Found Workshop. 2004; (46):33-45.
    View in: PubMed
    Score: 0.047
  32. Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line. Biophys J. 2022 10 04; 121(19):3651-3662.
    View in: PubMed
    Score: 0.043
  33. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. 2002 May; 9(5):359-64.
    View in: PubMed
    Score: 0.042
  34. A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Sci Transl Med. 2021 07 21; 13(603).
    View in: PubMed
    Score: 0.040
  35. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54.
    View in: PubMed
    Score: 0.040
  36. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019 10 22; 29(4):889-903.e10.
    View in: PubMed
    Score: 0.035
  37. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23; 95(7):927-37.
    View in: PubMed
    Score: 0.034
  38. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018 06 18; 9(1):2368.
    View in: PubMed
    Score: 0.032
  39. A "cross-stitched" peptide with improved helicity and proteolytic stability. Org Biomol Chem. 2018 05 23; 16(20):3702-3706.
    View in: PubMed
    Score: 0.032
  40. Estrogen receptor (alpha and beta) expression in the excurrent ducts of the adult male rat reproductive tract. J Androl. 1997 Nov-Dec; 18(6):602-11.
    View in: PubMed
    Score: 0.031
  41. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation. 1999 Oct 12; 100(15):1639-45.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.